Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. More Details
Proven track record with mediocre balance sheet.
Share Price & News
How has Catalent's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CTLT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CTLT's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CTLT exceeded the US Pharmaceuticals industry which returned 17.5% over the past year.
Return vs Market: CTLT underperformed the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Catalent's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StIf You Had Bought Catalent (NYSE:CTLT) Stock Five Years Ago, You Could Pocket A 373% Gain Today
1 month ago | Simply Wall StHere's Why We Think Catalent (NYSE:CTLT) Is Well Worth Watching
1 month ago | Simply Wall StHave Insiders Been Selling Catalent, Inc. (NYSE:CTLT) Shares This Year?
Is Catalent undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CTLT ($120.34) is trading above our estimate of fair value ($98.64)
Significantly Below Fair Value: CTLT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CTLT is poor value based on its PE Ratio (40x) compared to the US Pharmaceuticals industry average (23x).
PE vs Market: CTLT is poor value based on its PE Ratio (40x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: CTLT is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: CTLT is overvalued based on its PB Ratio (5.5x) compared to the US Pharmaceuticals industry average (2.9x).
How is Catalent forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTLT's forecast earnings growth (9.3% per year) is above the savings rate (2%).
Earnings vs Market: CTLT's earnings (9.3% per year) are forecast to grow slower than the US market (15% per year).
High Growth Earnings: CTLT's earnings are forecast to grow, but not significantly.
Revenue vs Market: CTLT's revenue (9.5% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: CTLT's revenue (9.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CTLT's Return on Equity is forecast to be low in 3 years time (14.8%).
How has Catalent performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTLT has a large one-off gain of $140.0M impacting its March 31 2021 financial results.
Growing Profit Margin: CTLT's current net profit margins (13.2%) are higher than last year (3.6%).
Past Earnings Growth Analysis
Earnings Trend: CTLT's earnings have grown significantly by 23.9% per year over the past 5 years.
Accelerating Growth: CTLT's earnings growth over the past year (373.6%) exceeds its 5-year average (23.9% per year).
Earnings vs Industry: CTLT earnings growth over the past year (373.6%) exceeded the Pharmaceuticals industry 12.9%.
Return on Equity
High ROE: CTLT's Return on Equity (13.7%) is considered low.
How is Catalent's financial position?
Financial Position Analysis
Short Term Liabilities: CTLT's short term assets ($2.8B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: CTLT's short term assets ($2.8B) do not cover its long term liabilities ($3.6B).
Debt to Equity History and Analysis
Debt Level: CTLT's debt to equity ratio (74.6%) is considered high.
Reducing Debt: CTLT's debt to equity ratio has reduced from 299.5% to 74.6% over the past 5 years.
Debt Coverage: CTLT's debt is not well covered by operating cash flow (15.5%).
Interest Coverage: CTLT's interest payments on its debt are well covered by EBIT (6x coverage).
What is Catalent current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTLT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTLT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Chiminski (57 yo)
Mr. John R. Chiminski serves as Independent Director at Berkeley Lights, Inc. since May 14, 2021. Mr. Chiminski has been the Chief Executive Officer at Catalent, Inc. since March 2009 and has been its Chai...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD9.13M) is about average for companies of similar size in the US market ($USD11.19M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: CTLT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: CTLT's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.
Catalent, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Catalent, Inc.
- Ticker: CTLT
- Exchange: NYSE
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$20.499b
- Shares outstanding: 170.34m
- Website: https://www.catalent.com
Number of Employees
- Catalent, Inc.
- 14 Schoolhouse Road
- New Jersey
- United States
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four se...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/03 00:43|
|End of Day Share Price||2021/08/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.